Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696782 · ClinicalTrials.gov registry record · Phase 2
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
A Phase 2 study of Nonsmall Cell Lung Cancer Stage III and Unresectable Non-Small Cell Lung Carcinoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05696782 is a Phase 2 study of Nonsmall Cell Lung Cancer Stage III and Unresectable Non-Small Cell Lung Carcinoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05696782, a Phase 2 study of Nonsmall Cell Lung Cancer Stage III and Unresectable Non-Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Conditions Studied
Interventions
- DRUG Durvalumab
- OTHER the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)
- DIAGNOSTIC_TEST COPD Assessment Test (CAT)
- DIAGNOSTIC_TEST Modified Medical Research Council (mMRC) dyspnea scale
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05696782
The ClinicalTrials.gov registry entry for NCT05696782 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Nonsmall Cell Lung Cancer Stage III appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.
NCT05696782 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05696782 about?
NCT05696782 is a clinical study titled "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer". This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
What is the current status of trial NCT05696782?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-07-26. Estimated completion is 2027-04.
What conditions does trial NCT05696782 study?
This clinical trial studies the following conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II.
What interventions are being tested in trial NCT05696782?
The interventions under investigation include: Durvalumab (DRUG), the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30) (OTHER), COPD Assessment Test (CAT) (DIAGNOSTIC_TEST), Modified Medical Research Council (mMRC) dyspnea scale (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05696782?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696782 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonsmall Cell Lung Cancer Stage III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Nonsmall Cell Lung Cancer Stage III
All registered trials for this condition
Unresectable Non-Small Cell Lung Carcinoma
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.